inositol nicotinate
inositol nicotinate.JPG

inositol nicotinate

CLINICAL USE

Peripheral vascular disease

DOSE IN NORMAL RENAL FUNCTION

3 g daily in 2–3 divided doses, maximum 4 g daily

PHARMACOKINETICS

  • Molecular weight                           :810.7
  • %Protein binding                           :High
  • %Excreted unchanged in urine     : No data
  • Volume of distribution (L/kg)       :No data
  • half-life – normal/ESRD (hrs)      :24

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

    30–50 Dose as in normal renal function10–30 Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unknown dialysability. Dose as in normal renal function
  • HD                     :Unknown dialysability. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • None known

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    Slowly hydrolysed to nicotinic acid inositol nicotinate.



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs